Kamada (KMDA) Capital Expenditures (2012 - 2026)
Kamada's (KMDA) quarterly Capital Expenditures came in at -$2.1 million in Q2 2026, down 4.62% on a YoY basis from -$2.2 million in Q2 2025, and down 116.55% quarter-over-quarter from -$973000.0 in Q1 2026.
Analysis
Kamada (KMDA) Capital Expenditures (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Capital Expenditures for 15 consecutive years, with -$2.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Capital Expenditures fell 4.62% year-over-year to -$2.1 million; the trailing twelve-month figure through Jun 2026 stood at -$9.4 million (down 10.72% YoY), and the FY2025 full-year result was -$9.8 million, up 8.32% from the prior year.
- Capital Expenditures eased to -$2.1 million in Q2 2026 per KMDA's latest filing, from -$973000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at -$513000.0 in Q1 2022 and bottomed at -$3.6 million in Q3 2025.
- Historically, Capital Expenditures has averaged -$1.8 million across 5 years, with a median of -$1.9 million in 2023.
- The widest YoY moves for Capital Expenditures: up 49.1% in 2022, down 291.6% in 2022.
- Over 5 years, Capital Expenditures stood at -$977000.0 in 2022, then slumped by 102.05% to -$2.0 million in 2023, then sank by 48.13% to -$2.9 million in 2024, then rose by 5.1% to -$2.8 million in 2025, then gained by 24.07% to -$2.1 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$2.1 million, -$973000.0, and -$2.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -2.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.11 Mn |
| Mar 31, 2026 | -973,000.00 |
| Dec 31, 2025 | -2.78 Mn |
| Sep 30, 2025 | -3.59 Mn |
| Jun 30, 2025 | -2.01 Mn |
| Mar 31, 2025 | -1.47 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | -2.12 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -2.68 Mn |
| Dec 31, 2023 | -1.97 Mn |
| Sep 30, 2023 | -1.73 Mn |
| Jun 30, 2023 | -1.03 Mn |
| Mar 31, 2023 | -1.12 Mn |
| Dec 31, 2022 | -977,000.00 |
| Sep 30, 2022 | -1.62 Mn |
| Jun 30, 2022 | -678,000.00 |
| Mar 31, 2022 | -513,000.00 |
| Dec 31, 2021 | -744,000.00 |
| Sep 30, 2021 | -1.52 Mn |